AR072932A1 - Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, su preparacion, composicion farmaceutica que los comprende y su aplicacion en terapeutica de enfermedades mediadas por caseina quinasa epsilon y delta. - Google Patents
Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, su preparacion, composicion farmaceutica que los comprende y su aplicacion en terapeutica de enfermedades mediadas por caseina quinasa epsilon y delta.Info
- Publication number
- AR072932A1 AR072932A1 ARP090103069A ARP090103069A AR072932A1 AR 072932 A1 AR072932 A1 AR 072932A1 AR P090103069 A ARP090103069 A AR P090103069A AR P090103069 A ARP090103069 A AR P090103069A AR 072932 A1 AR072932 A1 AR 072932A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- cycloalkyl
- groups
- atom
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- -1 -NR4R5 Chemical group 0.000 abstract 1
- 101100219283 Amycolatopsis orientalis cyp165C4 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, composicion farmacéutica que los comprende y su uso en medicamentos para el tratamiento de trastornos del sueno y del ritmo circadiano, como así también de enfermedades causadas por la proliferacion de células tumorales. Reivindicacion 1: Compuesto que responde a la formula general (1) en la que R2 representa un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, alquil C1-4-oxi-alquilo C1-4, cicloalquiloxi C3-7-alquilo C1-4, cicloalquil C3-7-alquiloxi C1-4-alquilo C1-4, hidroxialquilo C1-6, fluoroalquilo C1-4; R3 representa un átomo de hidrogeno o un sustituyente elegido entre átomos de halogeno y grupos alquilo C1-3, -NR4R5, hidroxi o alquiloxi C1-4; A representa un grupo alquileno C1-7, opcionalmente sustituido con uno o dos grupos Ra; B representa un grupo alquileno C1-7 opcionalmente sustituido con un grupo Rb; L representa, o un átomo de nitrogeno opcionalmente sustituido con un grupo Rc o Rd, o un átomo de carbono sustituido con un grupo Re1 y un grupo Rd o dos grupos Re2; estando los átomos de carbono de A y B opcionalmente sustituidos con uno o varios grupos Rf idénticos o diferentes el uno del otro; Ra, Rb y Rc, se definen de forma que: dos grupos Ra pueden formar juntos un grupo alquileno C1-6; Ra y Rb pueden formar juntos un enlace o un grupo alquileno C1-6; Ra y Rc pueden formar juntos un enlace o un grupo alquileno C1-6; Rb y Rc pueden formar juntos un enlace o un grupo alquileno C1-6; Rd representa un grupo elegido entre el átomo de hidrogeno y los grupos alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, alquil C1-6-tio-alquilo C1-6, alquil C1-6-oxi-alquilo C1-6, fluoroalquilo C1-6, hidroxi-alquilo C1-6; Re1 representa un grupo -NR4R5 o una monoamina cíclica que contiene opcionalmente un átomo de oxigeno, estando la monoamina cíclica opcionalmente sustituida con uno o varios sustituyentes elegidos entre el átomo de fluor y los grupos alquilo C1-6, alcoxi C1-6, hidroxilo; dos Re2 forman con el átomo de carbono al que están unidos una monoamina cíclica que contiene opcionalmente un átomo de oxigeno, estando esta monoamina cíclica opcionalmente sustituida con uno o varios grupos Rf idénticos o diferentes el uno del otro; Rf representa un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, alquil C1-6-oxi-alquilo C1-6, cicloalquiloxi C3-7-alquilo C1-4, cicloalquil C3-7-alquiloxi C1-4-alquilo C1-4, hidroxi-alquilo C1-6 o fluoroalquilo C1-6; R4 y R5 representan, independientemente uno de otro, un átomo de hidrogeno o un grupo alquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, R7 y R8 representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-6; en el estado de base o de sal de adicion de ácido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8812608P | 2008-08-12 | 2008-08-12 | |
| FR0804573A FR2934994B1 (fr) | 2008-08-12 | 2008-08-12 | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072932A1 true AR072932A1 (es) | 2010-09-29 |
Family
ID=40512462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103069A AR072932A1 (es) | 2008-08-12 | 2009-08-10 | Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, su preparacion, composicion farmaceutica que los comprende y su aplicacion en terapeutica de enfermedades mediadas por caseina quinasa epsilon y delta. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110312934A1 (es) |
| EP (1) | EP2331546B1 (es) |
| JP (1) | JP2011530574A (es) |
| KR (1) | KR20110052708A (es) |
| CN (1) | CN102186852A (es) |
| AR (1) | AR072932A1 (es) |
| AT (1) | ATE543822T1 (es) |
| AU (1) | AU2009281056A1 (es) |
| BR (1) | BRPI0917939A2 (es) |
| CA (1) | CA2734077A1 (es) |
| FR (1) | FR2934994B1 (es) |
| IL (1) | IL211141A0 (es) |
| MX (1) | MX2011001667A (es) |
| RU (1) | RU2011109223A (es) |
| TW (1) | TW201011028A (es) |
| UY (1) | UY32046A (es) |
| WO (1) | WO2010018327A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| CA2818903C (en) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor |
| US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
| US8969565B2 (en) * | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| JP6426603B2 (ja) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ |
| EP2869822B1 (en) | 2012-07-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | Inhibitors of phosphodiesterase 10 enzyme |
| PL3597648T3 (pl) * | 2017-03-14 | 2023-07-24 | Daiichi Sankyo Company, Limited | METODA WYTWARZANIA 3,6-DIPODSTAWIONEJ POCHODNEJ IMIDAZO[1, 2-b]PIRYDAZYNY |
| EP4063370A1 (en) | 2021-03-23 | 2022-09-28 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Imidazo[1,2-b]pyridazine based tricyclic compounds as inhibitors of haspin and therapeutic uses thereof |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502734A (ja) * | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| FR2918061B1 (fr) * | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
-
2008
- 2008-08-12 FR FR0804573A patent/FR2934994B1/fr not_active Expired - Fee Related
-
2009
- 2009-08-10 AR ARP090103069A patent/AR072932A1/es unknown
- 2009-08-11 TW TW098126965A patent/TW201011028A/zh unknown
- 2009-08-12 RU RU2011109223/04A patent/RU2011109223A/ru not_active Application Discontinuation
- 2009-08-12 CN CN2009801403242A patent/CN102186852A/zh active Pending
- 2009-08-12 AT AT09737011T patent/ATE543822T1/de active
- 2009-08-12 BR BRPI0917939A patent/BRPI0917939A2/pt not_active Application Discontinuation
- 2009-08-12 EP EP09737011A patent/EP2331546B1/fr active Active
- 2009-08-12 US US13/058,665 patent/US20110312934A1/en not_active Abandoned
- 2009-08-12 AU AU2009281056A patent/AU2009281056A1/en not_active Abandoned
- 2009-08-12 WO PCT/FR2009/001001 patent/WO2010018327A1/fr not_active Ceased
- 2009-08-12 CA CA2734077A patent/CA2734077A1/fr not_active Abandoned
- 2009-08-12 UY UY0001032046A patent/UY32046A/es not_active Application Discontinuation
- 2009-08-12 JP JP2011522537A patent/JP2011530574A/ja not_active Withdrawn
- 2009-08-12 KR KR1020117005761A patent/KR20110052708A/ko not_active Withdrawn
- 2009-08-12 MX MX2011001667A patent/MX2011001667A/es not_active Application Discontinuation
-
2011
- 2011-02-09 IL IL211141A patent/IL211141A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110312934A1 (en) | 2011-12-22 |
| TW201011028A (en) | 2010-03-16 |
| WO2010018327A1 (fr) | 2010-02-18 |
| RU2011109223A (ru) | 2012-09-20 |
| AU2009281056A1 (en) | 2010-02-18 |
| CA2734077A1 (fr) | 2010-02-18 |
| EP2331546A1 (fr) | 2011-06-15 |
| UY32046A (es) | 2010-03-26 |
| CN102186852A (zh) | 2011-09-14 |
| BRPI0917939A2 (pt) | 2015-11-17 |
| EP2331546B1 (fr) | 2012-02-01 |
| JP2011530574A (ja) | 2011-12-22 |
| FR2934994B1 (fr) | 2010-09-17 |
| ATE543822T1 (de) | 2012-02-15 |
| KR20110052708A (ko) | 2011-05-18 |
| FR2934994A1 (fr) | 2010-02-19 |
| IL211141A0 (en) | 2011-04-28 |
| MX2011001667A (es) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072932A1 (es) | Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, su preparacion, composicion farmaceutica que los comprende y su aplicacion en terapeutica de enfermedades mediadas por caseina quinasa epsilon y delta. | |
| AR069269A1 (es) | Derivados de 6- cicloamino -3- (piridin-il) imidazo (1,2-beta)- piridazina, su preparacion y su aplicacion en terapeutica | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| CO6400139A2 (es) | Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
| PA8789901A1 (es) | Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta | |
| AR083058A1 (es) | Compuestos de estructura de imidazotriazinona | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| UY31730A (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica. | |
| CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
| AR098549A1 (es) | Derivados de amino pirimidina | |
| AR066879A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| PH12012501772A1 (en) | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors | |
| CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
| ECSP10010349A (es) | Derivados de ftalazinona | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| UY31728A (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica | |
| AR071857A1 (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| DOP2014000156A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PE20090049A1 (es) | Derivados de piridopirimidina como moduladores de la actividad de pde 4 | |
| NI201000124A (es) | Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica | |
| PE20140934A1 (es) | Derivados de pirazol | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |